Physician profile
Murrita Bolinger
NPI 1013912799
$672.83
in general payments reported to CMS, 2019-2025
14 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.15 · 2023: $178 · 2024: $268 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $197.32 | 2022-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $131.79 | 2023-2025 | |
| Lilly USA, LLC | $51.71 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $46.14 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.79 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $35.74 | 2023-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $32.32 | 2024 | |
| Pfizer INC. | $30.17 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.70 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.71 | 2025 | Fanapt |
| Amgen INC. | $16.13 | 2025 | Otezla |
| Exact Sciences Corporation | $15.22 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2025 | Breztri |
| Glaxosmithkline, LLC. | $13.47 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murrita Bolinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.